Gidding - Figure 18 - Additional issues
There are a number of additional issues in management of FH that should be considered.
- Genetic testing is much more common in Europe, and experience says that this
helps to confirm diagnosis. However, it is not universally recommended and it is
not universally paid for by insurance carriers. Nonetheless, genetic information
can occasionally provide valuable information in discriminating children with and
without FH, particularly those with borderline LDL
levels, and may also give insight into the severity of the mutation.
- It is extremely important not to consider noninvasive imaging for risk
stratification in these patients. There is no current role for noninvasive imaging
in the management of FH patients, as simply the presence of FH is enough to
establish an absolute need to initiate therapy and attempt to achieve risk reduction
through hitting target LDL levels.
Gidding S.
J Clin Lipidol.
2011; 5(6).
